Economy

Stemline Therapeutics, Inc. (NASDAQ:STML) Moving Today - Up by 29.38%

Stemline Therapeutic (NASDAQ:STML)'s trailing twelve month revenues are $1.2 Million, whereas its price to sales ratio for the same period is 274.93. Stemline Therapeutics has a one year low of $5.50 and a one year high of $14.60.

Stemline Therapeutics, Inc. had its "buy" rating reiterated by analysts at H.C. Wainwright. The stock grabbed 9 new institutional investments totaling 293,895 shares while 15 institutional investors sold out their entire positions totaling 2,238,882 shares.

For the Current Quarter, the growth estimate for Stemline Therapeutics, Inc.is -8.9%, while for the Next Quarter the stock growth estimate is -12.5%.

To gain some better insight into how Stemline Therapeutics, Inc.

QuinStreet, Inc. (NASDAQ:QNST)'s stock has performed at 96.01%.

Recently stock market analysts have updated their consensus ratings on shares of Stemline Therapeutics, Inc.

Many analysts have provided their estimated foresights on Stemline Therapeutics, Inc. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company's stock worth $102,000 after purchasing an additional 858 shares during the last quarter.

Insider trading over the last 12 months, however, paints a different picture. Furthermore on 11/13/13 Aegis Capital "Maintained" the stock to Buy at $70. Of those transactions, there were 508,053 shares of STML bought and 59,215 shares sold.

Stemline Therapeutic (NASDAQ:STML) shares traded 29.38% up during most recent session to reach at the closing price of $13.65. After this sale, 2,085,380 common shares of STML are directly owned by the insider, with total stake valued at $28,465,437.

The most recent non open market insider trade was completed by DOBMEIER ERIC on 06/19/2017, and was a acquisition of 10,000 shares with a final price of $0.

12/05/2016 - Stemline Therapeutics, Inc. had its "buy" rating reiterated by analysts at Jefferies. The original version of this report can be accessed at https://www.truebluetribune.com/2017/11/01/stemline-therapeutics-inc-stml-price-target-raised-to-38-00.html.

According to Stemline Therapeutics, Inc.'s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 48.57%. The third largest holder is Farallon Capital Management Llc, which now holds $12.21 million worth of this stock and that ownership represents almost 3.7% of its market capitalization.

There are 84 institutional holders with active positions, accounting for 12.28 million shares in total. The company's shares were given away at $8.16 per share worth to an income of some $19,111 on account of Hoberman Kenneth. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company's stock worth $117,000 after purchasing an additional 500 shares in the last quarter.



Like this

Latest


02 November 2017
Georgia, Alabama top 2 in playoff rankings, Penn State 7th
The three other undefeated playoff-eligible teams are No. 9 Wisconsin (8-0), No. 10 Miami (7-0) and No. 18 Central Florida (7-0). Notre Dame is coming off a dismal 4-8 season past year that made many suspect coach Brian Kelly was not long for South Bend.

02 November 2017
Illinois' new "Silver Search" helps find missing people suffering from Alzheimer's
The "Silver Search" campaign launched on Wednesday, November 1st, which is the start of Alzheimer's Disease Awareness Month. IL law enforcement will now get new training on how they can help people find loved ones with dementia who go missing.

02 November 2017
Stock Trading Watch for Engold Mines Ltd (EGM.V)
The Firm owns and operates three global cruise brands: Royal Caribbean International, Celebrity Cruises and Azamara Club Cruises. The company reported $1.71 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.67 by $0.04.

02 November 2017
Police looking for man suspected of kidnapping
Police arrested 36-year-old Timothy Wyatt into custody during a traffic stop early Wednesday. Police say a man broke into a woman's Autauga County home Monday morning and kidnapped her.

02 November 2017
Here's How Space Travel Changes the Brain
Researchers scanned astronauts' brains using magnetic resonance imaging before and after varying lengths of space missions. These changes may help explain some of the unusual symptoms that astronauts can experience when returning to Earth.

02 November 2017
There were 134 collisions in Edmonton Wednesday
The product, which is applied in a thin layer once per snowfall, prevents the snow from sticking to the pavement, the city said. Tecklenborg says the city is well-prepared for winter, with more than 150 pieces of snow removal equipment at its disposal.

02 November 2017
Here's How to Sign Up for a Pa. Medical Marijuana Card
Huskey are two of just seven doctors in the state's northcentral region to win initial approval following state-mandated training. The state health department has also created a list of more than 100 approved physicians who can prescribe medical marijuana.

02 November 2017
Discovering Momentum Stocks: New Residential Investment Corp. (NRZ), Costco Wholesale Corporation (COST)
The stock of New Residential Investment Corp (NYSE:NRZ) has "Overweight" rating given on Wednesday, August 10 by Barclays Capital. The stock of New Residential Investment Corp (NYSE:NRZ) has "Outperform" rating given on Thursday, February 25 by FBR Capital.

02 November 2017
Stocks To Watch This Week: Consolidated Edison, Inc. (ED), Exelon Corporation (EXC)
Here we will take a look at several key ratios for Exelon Corporation (NYSE: EXC ), starting with the Book to Market (BTM) ratio. Also, it has an estimated price-earnings (P/E) multiple of 14.02 and a trailing 12-month price-earnings (P/E) multiple of 21.15.

02 November 2017
Beyonce Knowles Will Play Nala in 'The Lion King' 2019 Remake!
For the trio of hyena henchmen, Disney has enlisted Florence Kasumba , Eric André , and Keegan-Michael Key. Beyonce Knowles-Carter has joined the cast in the adaptation of the Disney classic as Nala.



Recommended